v3.26.1
Consolidated Statements of Changes in Equity - USD ($)
Common Stock
Class A
Common Stock
Class B
Common Stock
Diamir Biosciences Corp.
Additional Paid in Capital
Diamir Biosciences Corp.
Additional Paid in Capital
Accumulated Deficit
Diamir Biosciences Corp.
Accumulated Deficit
Accumulated Other Comprehensive income (loss) Amount
Non- controlling interests Amount
Diamir Biosciences Corp.
Total
Balance at Dec. 31, 2022 $ 13,269,528 $ 22,437,754     $ 45,308,080   $ (65,337,075) $ 33,807 $ (7,878,789)   $ 7,833,305
Balance (in Shares) at Dec. 31, 2022 1,326,953 2,243,776                  
Adjustment for change of par value $ (13,269,514) $ (22,437,732)     35,707,246    
Issuance of shares to non-controlling interest     67,766   (67,766)  
Issuance of shares in exchange of share options and settlement of liabilities $ 1     3,078,195     3,078,196
Issuance of shares in exchange of share options and settlement of liabilities (in Shares) 70,430                  
Issuance of shares for share-based compensation $ 1     176,263     176,264
Issuance of shares for share-based compensation (in Shares) 65,770                  
Issuance of shares $ 2     1,575,560     1,575,562
Issuance of shares (in Shares) 215,959                  
Stock compensation expense     1,088,925     1,088,925
Conversion of convertible notes $ 13     5,999,987     6,000,000
Conversion of convertible notes (in Shares) 1,250,000                  
Exercise of share options     16,506     16,506
Exercise of share options (in Shares) [1] 791                    
Rounding up for reverse stock split        
Rounding up for reverse stock split (in Shares) 8,018                  
Exchange difference on translation of foreign operations       (44,430)   (44,430)
Net loss       (2,824,647) (1,516,328)   (4,340,975)
Balance at Dec. 31, 2023 $ 31 $ 22     93,018,528   (68,161,722) (10,623) (9,462,883)   15,383,353
Balance (in Shares) at Dec. 31, 2023 2,937,921 2,243,776                  
Balance at May. 31, 2023     $ 4,441 $ 4,440,256   $ (4,464,931)       $ (20,234)  
Balance (in Shares) at May. 31, 2023     4,440,891                
Stock compensation expense       194,846           194,846  
Discount on note payable to founder       35,063           35,063  
Net loss       (614,405)       (614,405)  
Balance at May. 31, 2024     $ 4,441 4,670,165   (5,079,336)       (404,730)  
Balance (in Shares) at May. 31, 2024     4,440,891                
Balance at Dec. 31, 2023 $ 31 $ 22     93,018,528   (68,161,722) (10,623) (9,462,883)   15,383,353
Balance (in Shares) at Dec. 31, 2023 2,937,921 2,243,776                  
Conversion of Class B Ordinary Shares to Class A Ordinary Shares $ 4 $ (4)        
Conversion of Class B Ordinary Shares to Class A Ordinary Shares (in Shares) 446,842 (446,842)                  
Disposal of NCI         4,639       (4,639)  
Exercise of share options $ 2     451,658     451,660
Exercise of share options (in Shares) 427,060                  
Exchange difference on translation of foreign operations       99,785   99,785
Net loss       (4,267,806) 110,069   (4,157,737)
Balance at Dec. 31, 2024 $ 37 $ 18     93,474,825   (72,429,528) 89,162 (9,357,453)   11,777,061
Balance (in Shares) at Dec. 31, 2024 3,811,823 1,796,934                  
Balance at May. 31, 2024     $ 4,441 4,670,165   (5,079,336)       (404,730)  
Balance (in Shares) at May. 31, 2024     4,440,891                
Stock compensation expense       20,418           20,418  
Discount on note payable to founder       24,970           24,970  
Net loss           (282,532)       (282,532)  
Balance at Nov. 30, 2024     $ 4,441 4,715,553   (5,361,868)       (641,874)  
Balance (in Shares) at Nov. 30, 2024     4,440,891                
Balance at May. 31, 2024     $ 4,441 4,670,165   (5,079,336)       (404,730)  
Balance (in Shares) at May. 31, 2024     4,440,891                
Stock compensation expense       24,312           24,312  
Discount on note payable to founder       34,692           34,692  
Net loss       (743,235)       (743,235)  
Balance at May. 31, 2025     $ 4,441 4,729,169   (5,822,571)       (1,088,961)  
Balance (in Shares) at May. 31, 2025     4,440,891                
Balance at Dec. 31, 2024 $ 37 $ 18     93,474,825   (72,429,528) 89,162 (9,357,453)   11,777,061
Balance (in Shares) at Dec. 31, 2024 3,811,823 1,796,934                  
Placing of Class A Ordinary Shares $ 15     2,699,185     2,699,200
Placing of Class A Ordinary Shares (in Shares) [1] 1,535,000                    
Issuance of Class A Ordinary Shares and Investor Warrants, net of issuance costs $ 10     873,178     873,188
Issuance of Class A Ordinary Shares and Investor Warrants, net of issuance costs (in Shares) [1] 1,000,000                    
Accretion of redemption value to contingently redeemable warrants     (47,000)     (47,000)
Exchange difference on translation of foreign operations       (181,472)   (181,472)
Net loss       (1,363,270) (13,160)   (1,376,430)
Balance at Dec. 31, 2025 $ 62 $ 18     $ 97,000,188   $ (73,792,798) $ (92,310) $ (9,370,613)   $ 13,744,547
Balance (in Shares) at Dec. 31, 2025 [1] 6,346,823 1,796,934                  
Balance at May. 31, 2025     $ 4,441 4,729,169   (5,822,571)       (1,088,961)  
Balance (in Shares) at May. 31, 2025     4,440,891                
Discount on note payable to founder       12,694           12,694  
Net loss           (409,955)       (409,955)  
Balance at Nov. 30, 2025     $ 4,441 $ 4,741,863   $ (6,232,526)       $ (1,486,222)  
Balance (in Shares) at Nov. 30, 2025     4,440,891                
[1] All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED’s 1 for 10 reverse stock split, which was effective on January 23, 2023.